RxDoctor Payments Data

Trudy Pang, MD

Neurology · Boston, MANPI 1366496440

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,350 of the $12,164 with a category attached, or 76.9%. Livanova USA, Inc. accounts for 81.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $5,865 and has fallen 99.2% since, to $47 in 2025.

$12,164in general payments, 2019–2025

Across 22 payments — averaging $552.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$10K
  • UCB, Inc.$2K
  • Medtronic$178
  • SK Life Science, Inc.$155
  • Acadia Pharmaceuticals Inc$24
$17,100in research payments, 2019–2025

Across 2 payments — averaging $8550.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$17K

What the payments were for

  • Consulting fees$1,80015%
  • Speaking & faculty fees$9,35077%
  • Travel & lodging$4974%
  • Food & beverage$5174%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,164 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$71,639
Medicare patients
191
Services billed
475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam108$284,241
Lamictal XrLamotrigine33$250,380
EpidiolexCannabidiol (Cbd)20$119,080
ZonegranZonisamide12$69,182
Lamotrigine ErLamotrigine64$37,744
KeppraLevetiracetam13$27,785
Lacosamide84$24,333
VimpatLacosamide17$17,764
Clobazam66$15,772
UbrelvyUbrogepant13$12,852
DepakoteDivalproex Sodium12$7,891
LamictalLamotrigine13$4,296
Felbamate17$4,277
Levetiracetam ErLevetiracetam34$3,502
Divalproex Sodium ErDivalproex Sodium45$3,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat$1,960$302,005125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →